GSA Capital Partners LLP Reduces Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

GSA Capital Partners LLP lowered its stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 33.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 15,446 shares of the company’s stock after selling 7,822 shares during the quarter. GSA Capital Partners LLP’s holdings in C4 Therapeutics were worth $88,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in shares of C4 Therapeutics in the second quarter worth about $45,000. B. Riley Wealth Advisors Inc. purchased a new stake in C4 Therapeutics in the 2nd quarter worth approximately $51,000. Caxton Associates LP bought a new stake in shares of C4 Therapeutics in the 1st quarter worth approximately $172,000. SG Americas Securities LLC purchased a new position in shares of C4 Therapeutics during the third quarter valued at approximately $142,000. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of C4 Therapeutics during the second quarter valued at approximately $125,000. Institutional investors own 78.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CCCC. Stephens began coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $20.00 target price on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

C4 Therapeutics Trading Up 3.1 %

Shares of C4 Therapeutics stock opened at $4.38 on Tuesday. C4 Therapeutics, Inc. has a 12 month low of $1.06 and a 12 month high of $11.88. The firm has a market capitalization of $309.18 million, a P/E ratio of -2.58 and a beta of 3.04. The business has a fifty day simple moving average of $5.64 and a two-hundred day simple moving average of $5.62.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The company had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. Analysts predict that C4 Therapeutics, Inc. will post -1.48 earnings per share for the current year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.